Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: Pharmacokinetics from a dose-finding study

Abstract Background As part of a program to develop a novel estradiol-releasing contraceptive vaginal ring (CVR), we evaluated the pharmacokinetic (PK) profile of CVRs releasing segesterone acetate (Nestorone® (NES)) combined with one of three different estradiol (E 2 ) doses. Study design A prospective, double-blind, randomized, multi-centered study to evaluate a 90-day CVR releasing NES [200 mcg/day] plus E 2 , either 10 mcg/day, 20 mcg/day, or 40 mcg/day in healthy reproductive-age women with regular cycles. Participants provided blood samples twice weekly for NES and E 2 levels during the first 60 days (ring 1) and the last 30 days (ring 2) of use. A subset underwent formal PK assessments at ring initiation, ring exchange (limited PK), and study completion. Results The main study enrolled 197 women; 22 participated in the PK substudy. Baseline characteristics between the main and PK participants were comparable, with an average BMI of 25.8 kg/m 2 (SD 4.3). In the PK substudy, all three rings showed similar NES PK: mean area under the curve (AUC (0–72) ) 34,181 pg*day/mL; concentration maximum ( C max ) 918 pg/mL; time to maximum concentration ( T max ) 3.5 h. For E 2, the C max occurred at 2 h, and was significantly higher with the 20 mcg/day ring (mean 390 pg/mL); 10 mcg/day, 189 pg/mL, p=.003; 40 mcg/day, 189 pg/mL, p 2 levels remained under 35 pg/mL during treatment. Conclusion PK parameters of NES were not affected when paired with different doses of E 2 , but E 2 levels from all three doses were lower than anticipated and no dose response was observed. Implications While these novel estradiol-releasing combination contraceptive vaginal rings provided sustained release of contraceptive levels of Nestorone over 90 days, the E 2 levels achieved were not consistent with bone protection, and a dose–response was not observed.